Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877)
HKEX:1877
Holding HK:1877?
Track your performance easily
1877 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$9.17 - HK$24.60
Previous CloseHK$9.9
Volume122.40K
Average Volume (3M)733.33K
Market Cap
HK$22.67B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Oct 25, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.24
Shares OutstandingN/A
10 Day Avg. Volume616,240
30 Day Avg. Volume733,333
Standard Deviation0.17
R-Squared0.08
Alpha0.00128
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)8.00
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Shanghai Junshi Biosciences Co., Ltd. Class H News
PremiumCompany Announcements
Junshi Biosciences Reports H1 2024 Fund Management
PremiumCompany Announcements
Shanghai Junshi Biosciences Announces ReorganizationPremiumCompany Announcements
Junshi Biosciences Optimizes JV Capital Structure
PremiumCompany Announcements
Shanghai Junshi Biosciences Sees Strong Growth
PremiumCompany Announcements
Junshi Biosciences Schedules Key Financial Review
PremiumCompany Announcements
Junshi Biosciences Advances Melanoma Treatment
PremiumCompany Announcements
Junshi Biosciences’ Drug Nears EU Approval
PremiumCompany Announcements
Shanghai Junshi’s New Cancer Drug Application AcceptedOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
2.85% Mutual Funds
1.70% Other Institutional Investors
95.45% Public Companies and
Individual Investors
1877 FAQ
What was Shanghai Junshi Biosciences Co., Ltd. Class H’s price range in the past 12 months?
Shanghai Junshi Biosciences Co., Ltd. Class H lowest stock price was HK$9.17 and its highest was HK$24.60 in the past 12 months.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s market cap?
Currently, no data Available
When is Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date?
Shanghai Junshi Biosciences Co., Ltd. Class H’s upcoming earnings report date is Oct 25, 2024 which is in 36 days.
How were Shanghai Junshi Biosciences Co., Ltd. Class H’s earnings last quarter?
Shanghai Junshi Biosciences Co., Ltd. Class H released its earnings results on Aug 31, 2024. The company reported -HK$0.726 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.726.
Is Shanghai Junshi Biosciences Co., Ltd. Class H overvalued?
According to Wall Street analysts Shanghai Junshi Biosciences Co., Ltd. Class H’s price is currently Overvalued.
Does Shanghai Junshi Biosciences Co., Ltd. Class H pay dividends?
Shanghai Junshi Biosciences Co., Ltd. Class H does not currently pay dividends.
What is Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate?
Shanghai Junshi Biosciences Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shanghai Junshi Biosciences Co., Ltd. Class H have?
Shanghai Junshi Biosciences Co., Ltd. Class H has 219,295,700 shares outstanding.
What happened to Shanghai Junshi Biosciences Co., Ltd. Class H’s price movement after its last earnings report?
Shanghai Junshi Biosciences Co., Ltd. Class H reported an EPS of -HK$0.726 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.931%.
Which hedge fund is a major shareholder of Shanghai Junshi Biosciences Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:1877
---
Shanghai Junshi Biosciences Co., Ltd. Class H Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
-24.97%
Trailing 12-Months
Asset Growth
-6.04%
Trailing 12-Months
Company Description
Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.
---
1877 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Budweiser Brewing Co. APAC Ltd.
―
Guan Chao Holdings Limited
―
China XLX Fertiliser Ltd.
―
Best Analysts Covering 1877
1 Year
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
reiterated a buy rating 11 months ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of 0.00% per trade.
---